Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

[View FULLTEXT] [Download PDF
Year : 2010  |  Volume : 56  |  Issue : 2  |  Page : 163-167  


M Bhattacharya1, K Rajeshwari1, B Dhingra2 
1 Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, India
2 Department of Hematology & Oncology, All India Institute of Medical Sciences, Delhi, India

Correspondence Address:
M Bhattacharya
Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi

Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

How to cite this article:
Bhattacharya M, Rajeshwari K, Dhingra B. Posaconazole.J Postgrad Med 2010;56:163-167

How to cite this URL:
Bhattacharya M, Rajeshwari K, Dhingra B. Posaconazole. J Postgrad Med [serial online] 2010 [cited 2021 Jun 21 ];56:163-167
Available from:;year=2010;volume=56;issue=2;spage=163;epage=167;aulast=Bhattacharya;type=0

Monday, June 21, 2021
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer